PNQ Pimobendan CAS 74150-27-9

Pimobendan More Info

Pimobendan is a benzimidazole-pyridazinone compound classified as an inodilator, primarily used in veterinary medicine to manage heart failure in dogs. It exhibits both positive inotropic (increasing the force of heart contractions) and vasodilatory effects, making it effective for treating congestive heart failure due to conditions such as mitral valve insufficiency and dilated cardiomyopathy.

Mechanism of Action

Pimobendan's mechanism of action involves several key processes:
Calcium Sensitization: It enhances the sensitivity of cardiac troponin to calcium ions, which improves myocardial contractility without significantly increasing intracellular calcium concentration. This allows for more efficient heart contractions with lower energy consumption.
Phosphodiesterase III Inhibition: Pimobendan inhibits phosphodiesterase III (PDE3), leading to increased levels of cyclic adenosine monophosphate (cAMP). This results in vasodilation and reduced afterload, decreasing the workload on the failing heart.
Vasodilation: By relaxing vascular smooth muscle, pimobendan decreases systemic vascular resistance, which helps improve cardiac output and reduce pulmonary congestion.

Applications

Congestive Heart Failure: Used in dogs to treat heart failure resulting from valvular insufficiency or dilated cardiomyopathy.
Cardiac Support: It may be used as part of a broader treatment regimen for managing chronic heart conditions in veterinary practice.

Routes of Administration

Pimobendan is typically administered via:
Oral Tablets: Commonly prescribed for daily use in dogs.
Oral Solutions: Available for pets that may have difficulty swallowing tablets.

Safety and Side Effects

While generally well-tolerated, pimobendan can cause side effects, including:
Common Side Effects: Gastrointestinal issues such as vomiting, diarrhea, decreased appetite, and lethargy.
Serious Side Effects: Rarely, it may lead to more severe reactions like tachycardia (rapid heart rate), syncope (fainting), seizures, or allergic reactions (e.g., difficulty breathing).
Monitoring Required: Regular veterinary check-ups are essential to monitor for potential adverse effects, especially in patients with pre-existing conditions or those on concurrent medications.

Pharmacokinetics

Absorption: Rapidly absorbed after oral administration with a bioavailability of approximately 60–65%. Food intake can decrease its bioavailability.
Distribution: Highly protein-bound (90–95%) in circulation, which may affect its pharmacological effects and interactions with other drugs.
Metabolism: Primarily metabolized by the liver into an active metabolite called O-desmethylpimobendan (ODMP), which has additional pharmacological effects. The half-life of pimobendan is about 0.4 hours, while ODMP has a longer half-life of approximately 2 hours.
Elimination: Excreted mainly through bile and feces.